Stock Market & Financial Investment News

News Breaks January 3, 2013 08:59 EDT ARIA ARIAD Iclusig faces some risk, says Oppenheimer After surveying doctors, Oppenheimer believes that physicians are more cautious about the side effects of ARIAD's Iclusig drug for refractory CML after the FDA forced the company to include a boxed warning for the drug. The firm sees some downside risk for consensus estimates and maintains a Perform rating on ARIAD, although it still has confidence in the drug's long-term outlook. News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 08:22 EDT ARIA ARIAD shares should be bought on weakness, says BMO Capital Subscribe for More Information May 16, 2013 07:29 EDT ARIA Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 7, 2013 12:02 EDT ARIA ARIAD management to meet with JMP Securities Subscribe for More Information 07:39 EDT ARIA ARIAD reports Q1 EPS (36c), consensus (38c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.